NEW YORK, September 29, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Geron Corporation (NASDAQ: GERN), VIVUS Inc.
(NASDAQ: VVUS), Halozyme Therapeutics Inc. (NASDAQ: HALO), Advaxis
Inc. (NASDAQ: ADXS), and Progenics Pharmaceuticals Inc. (NASDAQ:
PGNX). Free research report on Geron can be accessed at
https://www.erionline.net/GERN.pdf On Monday, September 28, 2015, the NASDAQ Composite
ended at 4,543.97, down 3.04%, the Dow Jones Industrial Average
declined 1.92%, to finish the day at 16,001.89, and the S&P 500
closed at 1,881.77, down 2.57%. The losses were broad based as all
the sectors ended the session in negative. Register for your
complimentary reports at the links given below.
Geron Corp.'s stock declined 5.57%, to close the day at
$2.88. The stock recorded a trading
volume of 3.46 million shares, much above its three months average
volume of 2.81 million shares. Over the last one month and over the
past three months, Geron Corp.'s shares have declined 6.49% and
29.58%, respectively. Furthermore, the stock has lost 11.38% since
the start of this year. The company's shares are trading 18.73%
below their 50-day moving average. Additionally, Geron Corp. has a
Relative Strength Index (RSI) of 35.14. Sign up and read the free
notes on GERN at:
https://www.erionline.net/GERN.pdf
On Monday, shares in VIVUS Inc. recorded a trading volume of
8.60 million shares, higher than their three months average volume
of 2.80 million shares. The stock ended the day 9.62% higher at
$1.71. Although, VIVUS Inc.'s stock
has surged 54.05% in the last one month, it has plummeted 26.61% in
the previous three months and 40.63% on YTD basis. The company is
trading above its 50-day moving average by 19.29%. Furthermore,
shares of VIVUS Inc. have an RSI of 60.20. The complimentary notes
on VVUS can be downloaded in PDF format at:
https://www.erionline.net/VVUS.pdf
Halozyme Therapeutics Inc.'s stock plummeted 9.49%, to close
Monday's session at $14.50. The stock
recorded a trading volume of 1.97 million shares, above its three
months average volume of 1.37 million shares. Over the last one
month and the previous three months, Halozyme Therapeutics Inc.'s
shares have declined 19.62% and 31.73%, respectively. However, the
stock has surged 50.26% since the start of this year. The company
is trading 26.95% and 13.78% below its 50-day and 200-day moving
averages, respectively. Furthermore, Halozyme Therapeutics Inc.'s
stock has an RSI of 29.07. Register for free on Equity Research
Institute and access the latest research on HALO at:
https://www.erionline.net/HALO.pdf
Advaxis Inc.'s stock finished Monday's session 11.60% lower at
$12.19. A total of 2.77 million
shares were traded, which was above its three months average volume
of 1.34 million shares. Over the last one month and the previous
three months, Advaxis Inc.'s shares have declined 18.57% and
29.37%, respectively. However, the stock has gained 52.18% since
the beginning of 2015. The company's shares are trading below their
50-day and 200-day moving averages by 23.40% and 19.87%,
respectively. Advaxis Inc.'s stock has an RSI of 35.51. The
complete research on ADXS is available for free at:
https://www.erionline.net/ADXS.pdf
On Monday, shares in Progenics Pharmaceuticals Inc. ended the
session 8.05% lower at $5.94. The
stock reported a trading volume of 1.26 million shares, close to
its three months average volume of 1.32 million shares. Shares of
the company traded at a PE ratio of 99.00. Progenics
Pharmaceuticals Inc.'s shares have declined 24.14% in the last one
month, 9.45% in the previous three months and 21.43% on YTD basis.
The company is trading 24.12% below its 50-day moving average and
11.76% below its 200-day moving average. Moreover, shares of
Progenics Pharmaceuticals Inc. have an RSI of 28.67. Free in-depth
research on PGNX is available at:
https://www.erionline.net/PGNX.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net